Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effect of NovoMix 30, Levemir or NovoRapid (Alone or in Combination) in Subjects With Type 2 Diabetes Previously Treated With Other Anti-Diabetic Medication. A 24-Week, International, Prospective, Multi-Centre, Open-Labelled, Non-Interventional Study.

Next Previous
Trial Profile

The Effect of NovoMix 30, Levemir or NovoRapid (Alone or in Combination) in Subjects With Type 2 Diabetes Previously Treated With Other Anti-Diabetic Medication. A 24-Week, International, Prospective, Multi-Centre, Open-Labelled, Non-Interventional Study.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin detemir (Primary) ; Insulin aspart/insulin protamine aspart
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms A1chieve
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 20 Apr 2011 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
    • 20 Apr 2011 Actual end date reported as Dec 2010 by ClinicalTrials.gov.
    • 19 Jul 2010 The results of this study will be available in 2011, according to a Novo Nordisk media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top